Literature DB >> 2319941

Chlorpromazine-induced immunopathy: progressive increase in serum IgM.

S Zucker1, H M Zarrabi, W H Schubach, A Varma, R Derman, R M Lysik, G Habicht, P M Seitz.   

Abstract

Long-term chlorpromazine therapy has been associated with the asymptomatic development of a high incidence of antinuclear antibodies, coagulation inhibitors, and increased serum levels of IgM. The purpose of this study has been to characterize the natural history of this chlorpromazine-induced (CPZ) immunopathy. To this end we carried out a prospective study of schizophrenic patients with the immunopathy to compare the effect of continuing CPZ versus switching to haloperidol therapy. Although no marked differences were noted between the 2 groups at the end of 5 years, 6 of 29 patients who continued to receive CPZ, as compared to none of 14 patients on haloperidol, had progressive elevations of serum IgM. In spite of a high incidence of antinuclear antibodies, none of the patients developed a lupus-like syndrome. One patient, however, who had been maintained on CPZ for more than 15 years, developed Waldenström macroglobulinemia, as characterized by an IgM monoclonal gammopathy and a lymphocyte immunoglobulin heavy and kappa light chain gene rearrangement. Another CPZ-treated patient developed immune thrombocytopenia. Based on the potential serious sequelae of prolonged stimulation of the immune system by CPZ, we recommend that patients who develop an increase in serum IgM while on CPZ be switched to other types of anti-psychotic medications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2319941

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  4 in total

1.  Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes.

Authors:  Iwona Karwaciak; Kaja Karaś; Anna Sałkowska; Joanna Pastwińska; Marcin Ratajewski
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

2.  Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-05-16       Impact factor: 1.291

3.  MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.

Authors:  Annelies Demeyer; Ioannis Skordos; Yasmine Driege; Marja Kreike; Tino Hochepied; Mathijs Baens; Jens Staal; Rudi Beyaert
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

4.  [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-04-29       Impact factor: 1.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.